AU2021376124A1 - Peptide formulations and methods of use - Google Patents

Peptide formulations and methods of use Download PDF

Info

Publication number
AU2021376124A1
AU2021376124A1 AU2021376124A AU2021376124A AU2021376124A1 AU 2021376124 A1 AU2021376124 A1 AU 2021376124A1 AU 2021376124 A AU2021376124 A AU 2021376124A AU 2021376124 A AU2021376124 A AU 2021376124A AU 2021376124 A1 AU2021376124 A1 AU 2021376124A1
Authority
AU
Australia
Prior art keywords
composition
seq
administration
lipid
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021376124A
Other languages
English (en)
Inventor
Kenji Cunnion
Neel K. Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Realta Life Sciences Inc
Original Assignee
Realta Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Life Sciences Inc filed Critical Realta Life Sciences Inc
Publication of AU2021376124A1 publication Critical patent/AU2021376124A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2021376124A 2020-11-09 2021-11-03 Peptide formulations and methods of use Pending AU2021376124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111367P 2020-11-09 2020-11-09
US63/111,367 2020-11-09
PCT/US2021/057802 WO2022098682A1 (en) 2020-11-09 2021-11-03 Peptide formulations and methods of use

Publications (1)

Publication Number Publication Date
AU2021376124A1 true AU2021376124A1 (en) 2023-06-29

Family

ID=81457409

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021376124A Pending AU2021376124A1 (en) 2020-11-09 2021-11-03 Peptide formulations and methods of use

Country Status (10)

Country Link
US (1) US20230414506A1 (https=)
EP (1) EP4240392A4 (https=)
JP (1) JP2023549126A (https=)
KR (1) KR20230106643A (https=)
CN (1) CN116437938A (https=)
AU (1) AU2021376124A1 (https=)
CA (1) CA3194447A1 (https=)
IL (1) IL302567A (https=)
MX (1) MX2023005395A (https=)
WO (1) WO2022098682A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013955A2 (en) * 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
PT2432489T (pt) * 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
SG11201510732VA (en) * 2013-07-26 2016-01-28 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
ES2875498T3 (es) * 2015-06-26 2021-11-10 Realta Holdings Llc Compuestos de péptidos sintéticos y procedimientos de uso
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins
US12018054B2 (en) * 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
EP3740074B1 (en) * 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2020243220A1 (en) * 2019-05-28 2020-12-03 Realta Holdings, Llc Pic1 peptide compositions and methods of use thereof for treatment of hypoxic ischemic encephalopathy

Also Published As

Publication number Publication date
JP2023549126A (ja) 2023-11-22
KR20230106643A (ko) 2023-07-13
IL302567A (en) 2023-07-01
US20230414506A1 (en) 2023-12-28
MX2023005395A (es) 2023-05-19
CA3194447A1 (en) 2022-05-12
WO2022098682A1 (en) 2022-05-12
EP4240392A1 (en) 2023-09-13
EP4240392A4 (en) 2024-10-09
CN116437938A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
JP2020504161A (ja) 結核菌シャペロニン６０．１ペプチドおよびその使用
US20230414506A1 (en) Peptide formulations and methods of use
JP2026065064A (ja) ペプチドおよび使用方法
AU2016202731B2 (en) Immune-modulating agents and uses therefor
US20240209036A1 (en) Peptides and methods of use
AU2009317889A1 (en) Cyclic peptides and uses thereof
US20230272012A1 (en) Peptides and methods of use
CN117396215A (zh) 肽和使用方法
WO2025129029A2 (en) Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof
JP2023548001A (ja) ペプチドおよび使用方法
JPH01230528A (ja) 結核症の治療改善剤